Other factors contributing to the high mortality of PDAC include the absence of biomarkers for early disease detection and the complexity of tumor biology and genomics, limiting the effectiveness of conventional medical therapy [9,10]. There are also complexities in the genetic mutations associated with PDAC; for instance, the pattern of the major genetic mutation seen in PDAC, that is, the activation of the oncogene KRAS is distinct from other malignancies in that KRAS mutation is an inciting event in PDAC, and is seen in the precursor lesions, Pancreatic intraepithelial neoplasia (PanIN). This evidence concerns the gene KRAS and neoplasm.